Janus Henderson Group Discloses 10.6% Passive Stake In Mirum Pharmaceuticals As Of June 28
$JHG
$MIRM
Investment Managers
Finance
Biotechnology: Pharmaceutical Preparations
Health Care
- Form 13G
- Form 13G
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/12/2024 | $37.00 | Equal Weight | Wells Fargo | |
| 9/9/2024 | $33.00 → $37.00 | Sell → Neutral | UBS | |
| 5/15/2024 | $34.00 → $37.00 | Hold → Buy | TD Cowen | |
| 4/17/2024 | $48.00 | Buy | Stifel | |
| 2/2/2024 | $28.00 → $31.00 | Underweight → Neutral | JP Morgan | |
| 1/5/2024 | $25.00 | Sell | UBS | |
| 1/4/2024 | $30.00 | Market Perform | TD Cowen | |
| 12/18/2023 | $60.00 → $58.00 | Buy | H.C. Wainwright |
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum's Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units ("RSUs") under Mirum's 2020 Inducement Plan. The Compensation Committee approved the awards as an inducement material to Dr. Quan's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $26.72 per share, Mirum's closing trading price on January 16, 2024, and will vest over four years, wi
Solid investment performance, with 75%, 71%, 67%, and 85% of assets under management ("AUM") outperforming relevant benchmarks on a one-, three-, five-, and 10-year basis, respectively, as of September 30, 2024 Consecutive quarters of net inflows with third quarter 2024 net inflows of US$0.4 billion Third quarter 2024 diluted EPS of US$0.17 includes a US$111.9 million non-cash, non-operating, accounting expense release. Adjusted diluted EPS of US$0.91 is an increase of 42% year over year AUM increased 6% quarter over quarter and 24% year over year to US$382.3 billion as of September 30, 2024 Returned US$102 million in capital to shareholders through dividends and share buybacks in
Janus Henderson Group plc (NYSE:JHG) will announce its third quarter 2024 results on Thursday, October 31, 2024, at 7:30 a.m. ET. A conference call and webcast to discuss the results will be held at 9:00 a.m. ET. Those wishing to participate in the conference call should call the applicable number below and reference the Janus Henderson Results Briefing (Conference ID: 008089): From: United States 833 470 1428 United Kingdom 0808 189 6484 All other countries +1 929 526 1599 To eliminate wait times, conference call participants may pre-register at https://www.netroadshow.com/events/login?show=efbea0db&confId=71288. After registering, a confirmatio
Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies LIVMARLI for treatment of PFIC granted marketing authorization in Europe Initiating LIVMARLI EXPAND study for pruritus in rare cholestatic conditions Conference call to provide business updates today, August 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for second quarter 2024 and provided a business update. "The second quarter was marked by significant achievements across both our commercial medicines and development p
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - JANUS HENDERSON GROUP PLC (0001274173) (Reporting)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November 6-9, 2024, in Hollywood, Florida. Data highlighting clinical benefit and real-world evidence for patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), treated with LIVMARLI® (maralixibat) oral solution, will be presented during the meeting. Highlighted below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the NASPGHAN Program Book. Full analyses will be available following their p
Solid investment performance, with 75%, 71%, 67%, and 85% of assets under management ("AUM") outperforming relevant benchmarks on a one-, three-, five-, and 10-year basis, respectively, as of September 30, 2024 Consecutive quarters of net inflows with third quarter 2024 net inflows of US$0.4 billion Third quarter 2024 diluted EPS of US$0.17 includes a US$111.9 million non-cash, non-operating, accounting expense release. Adjusted diluted EPS of US$0.91 is an increase of 42% year over year AUM increased 6% quarter over quarter and 24% year over year to US$382.3 billion as of September 30, 2024 Returned US$102 million in capital to shareholders through dividends and share buybacks in
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on October 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,100 shares of common stock and 17,050 restricted stock units ("RSUs") to four new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $38.48 per share, Mirum's closing trading price on October 10, 2024, and will vest over four years,
SC 13G - JANUS HENDERSON GROUP PLC (0001274173) (Filed by)
SC 13G - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - JANUS HENDERSON GROUP PLC (0001274173) (Filed by)
10-Q - JANUS HENDERSON GROUP PLC (0001274173) (Filer)
8-K - JANUS HENDERSON GROUP PLC (0001274173) (Filer)
D - JANUS HENDERSON GROUP PLC (0001274173) (Filer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - JANUS HENDERSON GROUP PLC (0001274173) (Issuer)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation of LIVMARLI evaluated in the MARCH Phase 3 study.
JP Morgan analyst Kenneth Worthington maintains Janus Henderson Group (NYSE:JHG) with a Neutral and raises the price target from $36 to $38.
- Form 13G
Wells Fargo initiated coverage of Janus Henderson Group with a rating of Equal Weight and set a new price target of $37.00
UBS upgraded Janus Henderson Group from Sell to Neutral and set a new price target of $37.00 from $33.00 previously
TD Cowen upgraded Janus Henderson Group from Hold to Buy and set a new price target of $37.00 from $34.00 previously